Prescription Required
Formulation: Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Tablet
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Myleran is a prescription chemotherapy medication used to treat certain blood cancers, particularly chronic myeloid leukemia (CML).
It contains busulfan, an active ingredient that helps slow or stop the growth of abnormal blood cells by damaging their DNA.
Myleran belongs to a class of medications called alkylating agents. These medications interfere with the genetic material inside cells, preventing them from growing and multiplying normally.
Chronic myeloid leukemia is a type of cancer that affects the blood and bone marrow. It causes the body to produce excessive numbers of abnormal white blood cells, which can interfere with normal blood cell production.
Myleran helps reduce the number of abnormal blood cells and may improve symptoms associated with the disease.
Busulfan is also used in certain chemotherapy regimens before bone marrow or stem cell transplantation. However, the intravenous form is commonly used for this purpose, and transplant conditioning is not an approved indication for Myleran oral tablets in the United States.
Myleran is a powerful chemotherapy medication that requires close medical supervision and regular blood tests because it can severely suppress bone marrow function.Â
Myleran is indicated for the palliative treatment of chronic myeloid leukemia, also called chronic myelogenous leukemia.
Chronic myeloid leukemia is a blood cancer that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells.
Normally, the bone marrow produces red blood cells, white blood cells, and platelets in carefully controlled amounts.
White blood cells help the body fight infections, while red blood cells carry oxygen and platelets help prevent excessive bleeding.
In patients with CML, the bone marrow produces too many abnormal white blood cells.
These abnormal cells can accumulate in the bloodstream and bone marrow, interfering with normal blood cell production.
Patients may experience tiredness, unexplained weight loss, night sweats, abdominal discomfort, or an enlarged spleen.
Myleran helps control the disease by interfering with the DNA of rapidly dividing cells.
This reduces the production of abnormal white blood cells and may help relieve certain symptoms.
However, Myleran is not considered a cure for CML.
Modern targeted treatments, particularly tyrosine kinase inhibitors, are generally preferred for most patients with newly diagnosed CML.
Myleran may still be considered in selected circumstances when other treatments are unsuitable.
Myleran helps control abnormal blood cell production in certain patients with CML, but it does not eliminate the underlying cause of the disease.
Busulfan may also be used as part of a conditioning regimen before a bone marrow or hematopoietic stem cell transplant.
A stem cell transplant is a medical procedure that replaces damaged or diseased blood-forming cells with healthy stem cells.
Stem cells are specialized cells that can develop into different types of blood cells.
Before transplantation, patients may receive high-dose chemotherapy to destroy diseased bone marrow cells and create space for transplanted stem cells.
This treatment is called conditioning therapy.
Busulfan may be included in conditioning regimens because it strongly suppresses the production of blood cells in the bone marrow.
This helps prepare the body for the transplantation of healthy blood-forming stem cells.
Busulfan may be combined with other chemotherapy medications, depending on the type of transplant and underlying disease.
However, it is important to distinguish between different busulfan formulations.
Intravenous busulfan, including the Busulfex formulation, is approved for certain transplant conditioning regimens, while Myleran oral tablets have a different approved indication.
A transplant specialist determines the appropriate formulation, dosage, and treatment schedule.
Patients receiving busulfan-based conditioning require intensive monitoring because the treatment can cause severe bone marrow suppression and other serious complications.Â
Myleran contains busulfan, a chemotherapy medication that interferes with the DNA inside cells.
DNA contains the genetic instructions that cells need to grow, divide, and function.
Cancer cells often multiply more rapidly or in a less controlled way than healthy cells.
Myleran works by attaching chemical groups to DNA and causing damage that interferes with normal cell division.
This prevents susceptible cells from multiplying and may eventually cause them to die.
Damages DNA in Abnormal Blood Cells
Busulfan forms chemical bonds with DNA, which can prevent cells from copying their genetic material correctly.
Without proper DNA replication, cancer cells cannot continue dividing normally.
This helps reduce the number of abnormal blood cells produced in the bone marrow.
Suppresses Excessive Blood Cell Production
In patients with CML, the bone marrow produces too many abnormal white blood cells.
Myleran helps reduce this excessive production.
As abnormal blood cell counts decrease, certain symptoms associated with leukemia may improve.
Affects Healthy Bone Marrow Cells
Although Myleran targets rapidly dividing cells, it can also affect healthy cells in the bone marrow.
This may reduce the production of normal white blood cells, red blood cells, and platelets.
Severe bone marrow suppression can increase the risk of infections, anemia, and bleeding.
For this reason, regular blood tests are essential throughout treatment.
Myleran works by damaging DNA and reducing abnormal blood cell production, but it can also suppress healthy bone marrow function.
The time needed for Myleran to produce noticeable effects depends on the condition being treated, prescribed dosage, and individual response.
When used for chronic myeloid leukemia, Myleran may gradually reduce abnormal white blood cell counts over several weeks.
Your healthcare provider will monitor your blood test results to determine how well the medication is working.
Some patients may notice improvements in symptoms such as fatigue or abdominal discomfort as abnormal blood cell counts decrease.
However, the response varies among individuals.
Because busulfan can continue affecting bone marrow function after a dose is reduced or stopped, careful monitoring is important.
Your healthcare provider may adjust or temporarily discontinue treatment based on your blood cell counts.
Do not change your Myleran dosage or stop treatment without instructions from your oncology team.
Myleran is available as an oral tablet, commonly containing 2 mg of busulfan.
It should only be prescribed and monitored by a healthcare provider experienced in cancer chemotherapy.
Possible side effects include nausea, loss of appetite, skin pigmentation changes, and reduced blood cell counts.
More serious complications may include severe bone marrow suppression, lung damage, liver problems, infertility, and an increased risk of certain secondary cancers.
Myleran can also harm an unborn baby and should not be used during pregnancy unless a specialist determines that treatment is necessary under exceptional circumstances.
Your healthcare provider will recommend regular blood tests to monitor your response and detect complications early.
Seek urgent medical attention if you develop fever, unusual bleeding, severe weakness, or difficulty breathing during Myleran treatment.
Myleran is a potent chemotherapy medication and should only be used as part of an individualized cancer treatment plan under close medical supervision.Â
Myleran is a prescription chemotherapy medication used to treat certain blood cancers, particularly chronic myeloid leukemia (CML).
It contains busulfan, an alkylating agent that helps control the growth of abnormal blood cells by interfering with their DNA.
Myleran is available as an oral tablet, commonly containing 2 mg of busulfan.
The tablets are usually taken once daily or according to a schedule determined by your healthcare provider.
Myleran can generally be taken with or without food. Swallow the tablets with water and follow your prescribed dosage carefully.
The appropriate dose depends on your medical condition, body weight, blood cell counts, response to treatment, and other medical factors.
Your healthcare provider may adjust your dosage or temporarily stop treatment if your blood cell counts become too low.
Because Myleran can strongly suppress bone marrow function, regular blood tests are essential throughout treatment.
Take Myleran exactly as prescribed. Do not increase your dosage, take additional tablets, or change your treatment schedule without consulting your oncology team.
Myleran tablets are taken by mouth according to the instructions provided by your healthcare provider.
Swallow the tablets with a glass of water.
Do not crush, chew, or split the tablets unless your pharmacist or oncology team has specifically provided an approved method for handling them.
Myleran is a cytotoxic medication, meaning it can damage living cells.
Breaking or crushing the tablets may release medication particles or dust that could expose other people to the drug.
If you take Myleran once daily, try to take it at approximately the same time each day.
Follow your prescription label carefully, as chemotherapy dosing schedules may differ between patients.
Do not take extra tablets if you think your medication is not working quickly enough.
Myleran must be taken according to your individualized chemotherapy treatment plan because incorrect dosing can cause severe or prolonged bone marrow suppression.
The recommended dosage of Myleran depends on the condition being treated and your response to chemotherapy.
For patients with chronic myeloid leukemia, your healthcare provider may calculate the starting dose based on body weight and other clinical factors.
The dosage may be adjusted according to blood test results, particularly white blood cell and platelet counts.
Myleran can continue affecting bone marrow function after treatment has been reduced or stopped.
For this reason, your healthcare provider may temporarily interrupt treatment before blood counts become dangerously low.
Some patients may require lower maintenance doses or periods without treatment.
There is no single dosage that is appropriate for every patient.
Do not calculate or change your Myleran dosage on your own. Your oncology team will determine the appropriate amount based on your blood test results and treatment response.
Myleran tablets can generally be taken with or without food.
If you experience mild nausea or stomach discomfort, taking the medication with food may help.
However, follow any specific meal-related instructions provided by your oncology team.
Some patients receiving chemotherapy may experience reduced appetite, nausea, or changes in their normal eating habits.
Tell your healthcare provider if these symptoms make it difficult to take your medication or maintain adequate nutrition.
Do not take additional Myleran tablets if you vomit after a dose unless your oncology team specifically instructs you to do so.
Follow your prescribed dosing schedule and contact your healthcare provider if nausea or vomiting interferes with treatment.
Myleran affects the bone marrow, where the body produces red blood cells, white blood cells, and platelets.
Although this effect helps control abnormal blood cell production in leukemia, Myleran can also reduce healthy blood cell counts.
A low white blood cell count may increase the risk of infection.
A low red blood cell count can cause anemia, leading to tiredness, weakness, or shortness of breath.
A low platelet count may increase the risk of bruising or bleeding.
Your healthcare provider will arrange regular complete blood count (CBC) tests to monitor these changes.
The frequency of testing depends on your treatment stage and medical condition.
Because busulfan can cause delayed and prolonged bone marrow suppression, monitoring may need to continue after treatment is interrupted.
Attend every scheduled blood test and oncology appointment, even if you feel well and have no noticeable side effects.
Your healthcare provider may temporarily stop Myleran if your blood cell counts become too low or decrease more quickly than expected.
Myleran works by suppressing abnormal blood cell production in the bone marrow.
However, it can also reduce the production of healthy blood cells.
This may cause low white blood cell counts, anemia, or thrombocytopenia, a condition involving reduced platelet levels.
If your blood counts fall too low, you may be at increased risk of serious infections, weakness, or bleeding.
Your healthcare provider may recommend temporarily stopping treatment, reducing the dosage, or continuing close laboratory monitoring.
Because busulfan’s effects on the bone marrow can continue after the medication is stopped, blood cell counts may decrease further before recovering.
Do not restart Myleran after a treatment interruption unless your oncology team specifically instructs you to do so.
If you forget to take Myleran, contact your oncology team or pharmacist for instructions.
Because Myleran is a potent chemotherapy medication, the safest approach depends on your prescribed schedule and treatment plan.
Do not automatically take an extra tablet or double your next dose to replace a missed dose.
Taking additional Myleran can increase the risk of severe bone marrow suppression and other serious complications.
Your healthcare provider will determine whether the missed dose should be skipped or whether your treatment schedule needs to be adjusted.
Never take a double dose of Myleran to make up for a missed dose.Â
Myleran is a cytotoxic medication, meaning it can damage healthy cells as well as cancer cells.
For this reason, the tablets should be handled carefully to prevent unnecessary exposure.
Keep the tablets in their original packaging until you are ready to take your prescribed dose.
Swallow each tablet whole with water.
Do not crush, break, or chew the tablets because doing so may release medication dust.
Avoid touching broken or damaged tablets with bare hands.
If a tablet breaks or becomes damaged, ask your oncology pharmacist how to handle and dispose of it safely.
Wash your hands after handling the medication.
Intact, coated Myleran tablets generally present a much lower handling risk than crushed or broken tablets.
Never crush or split Myleran tablets because this may expose you or others to hazardous medication particles.Â
Myleran can harm a developing baby because busulfan interferes with DNA and normal cell division.
Pregnant individuals and those who may become pregnant should avoid unnecessary exposure to the medication.
This is particularly important when tablets are broken, crushed, or damaged because medication dust may come into contact with the skin or be inhaled.
If a household member is pregnant, another adult should handle the medication whenever possible.
Caregivers who must handle Myleran should follow the safety instructions provided by the oncology team or pharmacist.
These instructions may include wearing disposable gloves and washing hands after handling the tablets.
Do not crush tablets or prepare Myleran in a way that releases medication dust.
Pregnant individuals should avoid handling broken or crushed Myleran tablets. Ask your oncology pharmacist about safe handling arrangements if someone in your household is pregnant.
Taking more Myleran than prescribed can cause serious or life-threatening complications.
An overdose may severely suppress bone marrow function, reducing the body’s ability to produce healthy blood cells.
This can increase the risk of infection, anemia, and uncontrolled bleeding.
Symptoms may not appear immediately because the effects of busulfan on the bone marrow can be delayed.
Other possible effects include nausea, vomiting, diarrhea, weakness, and changes in liver function.
If you accidentally take more Myleran than prescribed, seek immediate medical attention or contact a poison control center, even if you feel well.
Do not wait for symptoms to develop before seeking help.
Myleran is a powerful chemotherapy medication that requires careful dosing, safe handling, and regular medical supervision.
Take the medication only according to your prescribed treatment schedule.
Swallow the tablets whole and avoid breaking, crushing, or chewing them.
Attend all scheduled blood tests so your oncology team can monitor your bone marrow function and adjust treatment when necessary.
Tell your healthcare provider if you develop fever, chills, unusual bruising, bleeding, severe tiredness, or difficulty breathing.
Avoid handling damaged tablets without appropriate protection, and keep Myleran away from children and pets.
Seek urgent medical attention if you develop a fever of 38°C (100.4°F) or higher, unexpected bleeding, or signs of a serious infection during Myleran treatment.
Follow your oncology team’s instructions carefully and do not change, interrupt, or restart Myleran treatment without medical guidance.
Myleran (Busulfan) is available in the following forms and strength:
Myleran may increase the risk of developing certain secondary blood cancers, including acute leukemia, particularly with prolonged exposure.
Myleran contains busulfan, a chemotherapy medication that damages DNA in cells to prevent them from growing and multiplying.
Although this action helps control abnormal blood cell production in chronic myeloid leukemia (CML), it can also damage the DNA of healthy cells.
Over time, damage to healthy blood-forming cells may contribute to the development of a new cancer.
This is called a secondary malignancy, meaning a cancer that develops after treatment for another disease.
The risk depends on several factors, including the total amount of busulfan received, treatment duration, previous chemotherapy, and individual health conditions.
However, not every patient taking Myleran will develop a secondary cancer.
Your healthcare provider will consider these risks when determining whether Myleran is appropriate for your condition.
Myleran has been associated with an increased risk of secondary leukemia and other cancers. Regular medical monitoring is important, particularly during prolonged treatment.Â
Tell your healthcare provider about any existing medical conditions before starting Myleran.
Because Myleran is a powerful chemotherapy medication, certain conditions may increase the risk of treatment-related complications.
These include significant bone marrow suppression, active infections, liver disease, kidney problems, or existing lung disorders.
Bone marrow suppression occurs when the bone marrow cannot produce enough healthy blood cells.
Patients who already have low blood cell counts may be at greater risk of infection, anemia, and bleeding during Myleran treatment.
Liver or kidney problems may also affect how your body tolerates chemotherapy or other medications used during treatment.
Your oncology team will review your medical history, laboratory results, and current medications before recommending an appropriate treatment plan.
Additional testing or closer monitoring may be necessary for patients with existing health conditions.
Tell your healthcare provider about all your medical conditions, even if they are currently well controlled.
Myleran may cause temporary or permanent infertility in both men and women.
Infertility means being unable to conceive a child naturally.
Busulfan can damage rapidly dividing cells, including the reproductive cells involved in producing sperm and eggs.
In women, Myleran may affect ovarian function and cause irregular menstrual periods or the permanent loss of menstruation.
This may lead to premature ovarian insufficiency, a condition in which the ovaries stop functioning normally before the usual age of menopause.
In men, Myleran may reduce sperm production or cause permanent damage to the cells responsible for producing sperm.
The likelihood of infertility depends on the dosage, treatment duration, age, and other chemotherapy medications used.
Some patients may recover reproductive function after treatment, while others may experience permanent infertility.
If you want to have children in the future, discuss fertility preservation options before starting Myleran.
These may include sperm banking, egg freezing, or embryo freezing, depending on your circumstances.
Myleran may cause permanent infertility. Speak with your oncology team about fertility preservation before treatment begins.
Myleran can harm an unborn baby and should generally be avoided during pregnancy.
Busulfan interferes with DNA and cell division, processes that are essential for normal fetal development.
Exposure during pregnancy may increase the risk of miscarriage, birth defects, or other developmental complications.
Tell your healthcare provider if you are pregnant, planning to become pregnant, or think you may be pregnant before starting Myleran.
Your oncology team will discuss the risks of treatment and determine the most appropriate approach for your condition.
Patients who can become pregnant should use effective contraception during treatment and for the period recommended by their oncology team afterward.
Male patients with partners who may become pregnant should also discuss contraception because busulfan may damage reproductive cells.
Do not become pregnant during Myleran treatment. Contact your oncology team immediately if you become pregnant or suspect pregnancy.
Do not stop prescribed cancer treatment without urgent guidance from your oncology team.
Breastfeeding is not recommended during Myleran treatment.
It is not known whether busulfan passes into human breast milk in amounts that could affect a nursing infant.
However, because Myleran is a cytotoxic medication, exposure could potentially harm a developing baby.
Cytotoxic medications can damage healthy cells as well as cancer cells.
Infants may be particularly vulnerable because their organs and body systems are still developing.
If you are breastfeeding or planning to breastfeed, tell your healthcare provider before starting Myleran.
Your oncology team will help determine an appropriate feeding plan and advise when breastfeeding could safely resume after treatment.
Do not breastfeed while taking Myleran. Follow your oncology team’s instructions regarding breastfeeding after treatment ends.
One of the most serious risks associated with Myleran is bone marrow suppression, also called myelosuppression.
The bone marrow is the soft tissue inside bones responsible for producing blood cells.
It produces three important types of blood cells: red blood cells, white blood cells, and platelets.
Red blood cells carry oxygen throughout the body. White blood cells help fight infections, while platelets help stop bleeding.
Myleran works by damaging DNA in rapidly dividing cells, including cells in the bone marrow.
Although this helps reduce abnormal blood cell production in leukemia, it can also interfere with the production of healthy blood cells.
Severe bone marrow suppression may cause anemia, increased susceptibility to infections, and an increased risk of bleeding.
In rare cases, Myleran may cause aplastic anemia, a serious condition in which the bone marrow produces too few blood cells.
This damage may sometimes be prolonged or irreversible.
Your healthcare provider will arrange regular complete blood count (CBC) tests to monitor your blood cell levels.
Because Myleran’s effects can be delayed, blood cell counts may continue to fall even after treatment is reduced or stopped.
Myleran can cause severe, potentially irreversible bone marrow suppression. Attend all scheduled blood tests and report fever, unusual bruising, bleeding, or severe weakness immediately.Â
Myleran may cause changes in the skin during treatment.
One of the more commonly reported skin effects is hyperpigmentation, which causes certain areas of skin to become darker.
These changes may develop gradually during prolonged treatment.
Some patients may also experience dryness, itching, or a skin rash.
Other reported skin reactions include redness, irritation, and increased sensitivity.
Rarely, more serious skin reactions may occur, particularly in patients receiving other treatments that affect the skin.
For example, radiation therapy may increase skin reactions in areas previously exposed to certain chemotherapy medications.
Tell your healthcare provider if you develop a new rash, persistent irritation, or significant changes in skin appearance.
Your oncology team will determine whether the reaction is related to Myleran or another medication.
Contact your healthcare provider promptly if you develop a widespread rash, blistering, peeling skin, or other severe skin reactions.Â
Myleran may occasionally affect the nervous system, particularly when high doses of busulfan are used.
The nervous system includes the brain, spinal cord, and nerves responsible for controlling movement, sensation, and other body functions.
One of the more serious neurological complications associated with busulfan is seizures.
A seizure occurs when abnormal electrical activity in the brain causes sudden changes in movement, awareness, or consciousness.
Symptoms may include uncontrolled shaking, muscle stiffness, confusion, loss of awareness, or loss of consciousness.
The risk of seizures is especially important during high-dose busulfan treatment used in certain stem cell transplant conditioning regimens.
Patients receiving high-dose busulfan may be prescribed anticonvulsant medication to help prevent seizures.
Seizures are less commonly reported with conventional oral doses of Myleran, but patients with a history of epilepsy, head injuries, or other neurological conditions may require additional precautions.
Confusion and hallucinations should not automatically be attributed to Myleran. These symptoms may have other serious causes, including infections or metabolic disturbances, and require medical assessment.
Tell your healthcare provider if you have a history of seizures or other neurological conditions before starting Myleran. Seek emergency medical attention if a seizure occurs.Â
Myleran may increase the risk of developing a second cancer after treatment.
A secondary malignancy is a new cancer that develops separately from the original disease.
Busulfan is an alkylating agent that damages DNA to prevent abnormal cells from multiplying.
However, this effect is not limited to cancer cells.
Healthy cells may also experience DNA damage, which can contribute to the development of secondary malignancies.
These may include certain blood cancers and, potentially, other types of cancer.
The risk depends on treatment duration, cumulative medication exposure, previous cancer treatments, and individual patient factors.
Secondary cancers may develop years after the original treatment.
For this reason, long-term follow-up may be appropriate, even after Myleran has been discontinued.
Your healthcare provider will consider these risks when evaluating the expected benefits of treatment.
Myleran has been associated with secondary malignancies. Continue attending recommended medical appointments and cancer screenings during and after treatment.
Myleran may increase your risk of developing infections because it can suppress the production of white blood cells.
White blood cells are an important part of the immune system and help the body fight bacteria, viruses, and fungi.
When white blood cell counts become too low, the body may have difficulty controlling infections.
A low level of certain infection-fighting white blood cells is called neutropenia.
Patients with neutropenia may develop infections more easily, and infections may become serious more quickly.
Common warning signs include fever, chills, sore throat, persistent cough, painful urination, and unusual tiredness.
Some patients may develop infections without the usual signs of inflammation because their immune systems are weakened.
To reduce infection risk, follow your oncology team’s recommendations regarding handwashing, food safety, and contact with people who are ill.
Your healthcare provider may also recommend specific precautions when your blood cell counts are low.
A fever of 38°C (100.4°F) or higher during chemotherapy requires immediate medical assessment. Do not wait for other symptoms to develop.
Myleran may interact with certain prescription medications, over-the-counter products, and supplements.
Some medications may affect how quickly busulfan is processed and removed from the body.
This can increase busulfan exposure and raise the risk of toxicity.
Other medications may increase the risk of bone marrow suppression or damage to other organs when used alongside Myleran.
For example, combining Myleran with other chemotherapy medications that suppress bone marrow function may increase the likelihood of low blood cell counts.
Certain antifungal medications, including itraconazole, may also affect busulfan clearance, particularly during high-dose treatment.
Your oncology team will review your medications to identify potentially harmful combinations.
Do not assume that over-the-counter products, herbal supplements, or vitamins are safe to take during chemotherapy.
Tell your oncology team and pharmacist about all medications and supplements you use. Do not start, stop, or change another medication without medical guidance.Â
Hemorrhagic cystitis is a condition that causes inflammation and bleeding in the bladder.
Symptoms may include blood in the urine, painful urination, frequent urination, or discomfort in the lower abdomen.
Although hemorrhagic cystitis is a recognized complication of certain chemotherapy treatments, it is not a well-established direct adverse effect of Myleran oral tablets.
This condition is more strongly associated with chemotherapy medications such as cyclophosphamide and ifosfamide.
Patients receiving busulfan as part of a combination chemotherapy regimen may also receive other medications that can affect the bladder.
In addition, patients undergoing stem cell transplantation may develop urinary complications because of infections or other treatment-related factors.
If you notice blood in your urine or experience unusual urinary symptoms during Myleran treatment, contact your healthcare provider promptly.
Your oncology team may recommend urine tests or other examinations to determine the cause.
Report blood in your urine, painful urination, or other significant urinary changes during chemotherapy. These symptoms require medical evaluation.
Serious heart-related complications have occasionally been reported in patients receiving busulfan-based chemotherapy.
However, these complications are uncommon and are more strongly associated with certain high-dose treatment regimens than with conventional doses of Myleran oral tablets.
One reported complication is cardiac tamponade, a condition in which fluid builds up around the heart and interferes with its ability to pump blood.
Cardiac tamponade has been reported in some patients receiving high-dose busulfan together with cyclophosphamide before stem cell transplantation.
Rare cases of fibrosis affecting heart tissue have also been reported after prolonged busulfan exposure.
However, irregular heartbeats and reduced heart function are not established as common direct side effects of Myleran tablets.
Patients with existing heart disease should tell their oncology team before treatment begins.
Your healthcare provider may recommend additional monitoring depending on your medical history and the other chemotherapy medications included in your regimen.
Seek immediate medical attention if you experience chest pain, severe shortness of breath, fainting, or a persistent rapid or irregular heartbeat.Â
Another important risk associated with Myleran is lung toxicity.
In rare cases, busulfan can cause inflammation and scarring of lung tissue.
This condition is called pulmonary fibrosis.
Pulmonary fibrosis makes lung tissue thicker and less flexible, which can interfere with normal breathing and oxygen exchange.
Symptoms may include a persistent dry cough, shortness of breath, chest discomfort, and reduced ability to perform physical activities.
Lung damage may develop after prolonged treatment and can sometimes be serious or irreversible.
Patients receiving high-dose chemotherapy or other medications that affect the lungs may face additional risks.
Your healthcare provider may recommend lung function testing or imaging studies if respiratory symptoms develop.
Contact your oncology team promptly if you develop a new persistent cough, increasing shortness of breath, or unexplained breathing difficulties while taking Myleran.Â
Myleran is a powerful chemotherapy medication that requires close medical supervision.
The most important risks include severe bone marrow suppression, infections, bleeding, infertility, lung damage, and the potential development of secondary cancers.
Your oncology team will monitor your blood cell counts and may recommend additional tests depending on your medical condition and treatment response.
Do not increase, decrease, interrupt, or restart Myleran without instructions from your healthcare provider.
Report any unusual symptoms, particularly fever, unexpected bleeding, severe tiredness, persistent coughing, or difficulty breathing.
Seek urgent medical attention if you develop a fever of 38°C (100.4°F) or higher, uncontrolled bleeding, a seizure, severe chest pain, or significant breathing difficulties.
Regular blood tests, careful medication management, and scheduled oncology appointments are essential for reducing treatment-related risks and identifying complications early.
Yes. Myleran may cause temporary or permanent infertility in both men and women. Myleran contains busulfan, a chemotherapy medication that works by damaging DNA in rapidly dividing cells. Although this helps control cancer cells, it may also affect healthy reproductive cells involved in producing sperm and eggs. In women, Myleran may damage the ovaries and interfere with normal hormone production. This can cause irregular menstrual periods, the absence of menstruation, or premature ovarian insufficiency, a condition in which the ovaries stop functioning normally before the usual age of menopause. In men, Myleran may reduce sperm production or damage the cells responsible for producing sperm. In some cases, this can lead to permanent infertility. The risk depends on several factors, including the patient’s age, prescribed dosage, duration of treatment, and whether other chemotherapy medications are being used. Some patients may recover reproductive function after treatment, while others may experience permanent changes. If you are planning to have children in the future, speak with your oncology team before starting Myleran. Fertility preservation options, such as sperm banking, egg freezing, or embryo freezing, may be available. Myleran may cause permanent infertility in both men and women. Discuss fertility preservation options with your healthcare provider before beginning treatment.
Myleran can cause serious harm to a developing baby and should generally not be used during pregnancy. Busulfan interferes with DNA and normal cell division, which are essential processes during fetal development. Exposure during pregnancy may increase the risk of miscarriage, birth defects, or other developmental complications. Tell your healthcare provider if you are pregnant, planning to become pregnant, or think you may be pregnant before starting treatment. If you become pregnant while taking Myleran, contact your oncology team immediately. Your healthcare provider will assess the potential risks and determine the safest treatment approach for your medical condition. Patients who can become pregnant should use effective contraception during treatment and for the recommended period afterward. Male patients with partners who may become pregnant should also discuss contraception requirements with their healthcare provider. Breastfeeding is not recommended while taking Myleran. It is not known whether busulfan passes into human breast milk. However, because Myleran is a cytotoxic medication that can damage healthy cells, exposure may pose serious risks to a nursing infant. If you are breastfeeding, your healthcare provider will recommend an alternative feeding plan and advise when breastfeeding may safely resume after treatment. Do not breastfeed during Myleran treatment. Avoid pregnancy while receiving Myleran, and follow your oncology team’s instructions regarding contraception and pregnancy planning.
| Generic name: | Busulfan |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 2mg |
| Quantities Available: | 25 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Myleran (busulfan) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Myleran is available in 2 mg tablets and is commonly prescribed at a maximum dosage of 16 mg per day, usually taken as a single dose. For a 90-day supply, this means you would order up to 720 tablets (90 days x 8 tablets per day).
No, we don’t sell busulfan directly. However, you can still enjoy low prices on Myleran, which contains busulfan as an active ingredient. To purchase Myleran, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication safely and appropriately. You can submit your prescription by mailing it to us, faxing it, or uploading it through your online account.
Yes, we ship Myleran (busulfan) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Myleran (Busulfan). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Myleran (Busulfan).
REVIEWS